NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) hit a new 52-week low Friday as it is currently trading at $7.19, below its previous 52-week low of $7.20 with 102,690 shares traded as of 3:25 p.m. ET. Average volume has been 366,100 shares over the past 30 days.

Enzon has a market cap of $352.5 million and is part of the health care sector and drugs industry. Shares are down 39% year to date as of the close of trading on Thursday.

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs.
  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full Enzon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.